Survey: Physicians See Adalimumab (Humira) as Best Option for Treating Psoriatic Arthritis
Efficacy of TNF-alpha inhibitors may constrain emerging therapies (June 3)
Decision Resources, a research and advisory firm located in Burlington, Mass., finds that, based on the opinions of interviewed thought leaders and on clinical data, adalimumab (Humira; AbbVie/Eisai) has the strongest clinical profile among key marketed products that treat psoriatic arthritis (PsA).
None of the PsA therapies in development shows efficacy advantages over adalimumab, although certolizumab pegol (Cimzia; UCB/Astellas) has a similar clinical profile.
The survey also finds that, while other drugs in development hold promise, they have efficacy, safety, and tolerability and/or delivery disadvantages compared with adalimumab and certolizumab.
“The TNF [tumor necrosis factor]-alpha inhibitors have set a high clinical standard that is challenging for emerging therapies to surpass,” said analyst Bingnan Kang, PhD. “However, unmet needs exist for improvements in various efficacy, safety, tolerability, and delivery attributes. The PsA pipeline contains several agents with novel mechanisms of action that have the potential to fulfill some of these unmet needs.”
Physicians in the U.S. and Europe and pharmacy directors at U.S. managed care organizations (MCOs) identified new therapies with a greater ability to halt the progression of structural damage as a key unmet need. In addition, surveyed U.S. MCO pharmacy directors were particularly receptive to new PsA therapies that could offer improved effects on the signs and symptoms of arthritis over currently available therapies.
Improving signs and symptoms and inhibiting structural damage are two key treatment goals in the management of PsA.
Source: Decision Resources; June 3, 2013.